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Identity 
Other names: 16.3A5, 1F5, EJ16, EJ30, EL32, G344, 
HRF-20, HRF20, MAC-IP, MACIF, MEM43, MIC11, 
MIN1, MIN2, MIN3, MIRL, MSK21, p18-20 
HGNC (Hugo): CD59 
Location: 11p13 
Local order: FBOX3, CD59, C11orf91. 
Note 
CD59 gene encodes a ubiquitously expressed 
membrane-bound glycoprotein which inhibits 
complement system. More specifically, CD59 binds 
complement C8 and/or C9 during the assembly of the 
membrane attack complex, thus protecting self-cells 
from damage caused by the activation of the terminal 




NCBI Reference Sequence: NG_008057.1. 
Transcription 
- Total range: NG_008057.1 
- exon 1: (1..98); total length: 98; strand: plus 
- exon 2: (2870..2985); total length: 116; strand: plus 
- exon 3: (5012..5056); total length: 45; strand: plus 
- exon 4: (13528..13563); total length: 36; strand: plus 
- exon 5a: (13753..13844); total length: 92; strand: plus 
- exon 5b :(13753..13909); total length: 157; strand: 
plus 
- exon 5c: (13753..14101); total length: 349; strand: 
plus 
- exon 5d: (14017..14101); total length: 85; strand: plus 
- exon 6: (19009..19110); total length: 102; strand: plus 
- exon 7: (26137..33470); total length: 7,334; strand: 
plus. 
Transcription results in 22 different mRNAs (20 
alternatively spliced variants and 2 unspliced forms). 
Despite the very high number of different CD59 
transcripts, most of them vary at their 5' and/or 3' ends 
and encode a unique CD59 protein. However, different 
splicing variants have alternative promoters and 
stabilising sequences which is likely to affect the 
expression level of the protein. 
 
Red line marks the position of the CD59 gene in chromosome 11, p13. 
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CD59 gene consists of 7 exons and 6 introns spanning 1 to 33470bp of DNA (NCBI Reference Sequence: NG_008057.1) from 11p13 
and includes a 5'-/3'- non-coding regions. The position of exons is: 1..98 (exon 1), 2870..2985 (exon 2), 5012..5056 (exon 3), 
13528..13563 (exon 4), 13753..13844 (exon 5a), 13753..13909 (exon 5b), 13753..14101 (exon 5c), 14017..14101 (exon 5d), 
19009..19110 (exon 6), and 26137..33470 (exon 7). Highlighted in red is the protein coding sequence from exons 5c/5d, 6 and 7 
(14035..26354). 
 
Sequence of CD59 protein. CD59 contains 10 cystein residues involved in 5 disulphide bonds creating 5 loop structures. First three 
helical loops at the N-terminus form the hydrophobic core of CD59. Detailed information on CD59 protein structure can be obtained in 




CD59 is a 128aa-long protein. No polymorphisms have 
been described in the protein coding sequence of the 
CD59 gene. All transcription variants of CD59 result in 
the synthesis of a single CD59 protein with molecular 
mass between 18 and 22 kDa, depending on the level of 
glycosylation. CD59 has sites for both N- and O-
glycosylation. 
Expression 
CD59 is expressed in all organs and in almost all cel  
types. It is essential to protect cells from self-
destruction by complement-mediated lysis. The highest 
expression in humans has been detected in 
cardiomyocytes and smooth muscles (Su et al., 2004). 
Some nucleated blood cells (CD14 monocytes, T cells) 
either lack CD59 expression or express it very low 
which makes them highly susceptible to complement 
lysis. 
Localisation 
CD59 is expressed on the surface of cells. It is attached 
to the cellular membrane via a 
glycosylphosphatidylinositol tail (GPI-anchored 
molecule). In urine, CD59 can be found as soluble 
protein. 
Function 
The major and well-studied role of CD59 protein is to 
protect cells from self-destruction by our complement 
system. CD59 is the only membrane-bound inhibitor of 
the terminal pathway of complement cascade.  
However, in more recent years, some other functions of 
CD59 were described. CD59 was found to attenuate 
angiogenesis by preventing the complement-mediated 
lysis of newly grown blood vessels (Ekdahl et al., 
2006). In addition, it was found that via CD59, theLPS 
signal is transduced into the nucleus via NF-kappaB 
activation inducing cytokine generation (Yamamoto e 
al., 2003). 
Homology 
CD59 protein does not show significant homology with 
other proteins. However, there is a high cross-primates 
homology for CD59. Human CD59 has 84% homology 
with CD59 in Macaca fascicularis and 91% homology 
in Pongo abelii (BLAST search). Homology between 
human CD59 protein and CD59 in rodents, however, is 
less than 50% (BLAST analysis). 
Mutations 
Somatic 
No polymorphisms have been described for CD59 gene 
which affect the protein sequence. However, analysis 
of the sequence of the human CD59 gene revealed the 
presence of a (GT)19 dinucleotide repeat ~800bp 
upstream from exon 1 (Nöthen and Dewald, 1995). 
This polymorphism might affect expression and/or 
stability of CD59 transcripts, however, there is no
experimental information on this matter.  
A mutation in another gene, PIGA gene, however, 
indirectly results in lack of CD59 on red blood cells 
(RBCs). This condition is called paroxysmal nocturnal 
haemoglobinuria (PNH) and is a clonal disorder of 
RBCs. As a result of defective PIGA function, affected 
RBCs lack all GPI-linked membrane proteins, 
including CD59. The lack of CD59 renders PNH-RBCs 
susceptible to autologous complement lysis (Botto e 
al., 2009). 
Implicated in 
Paroxysmal nocturnal hemoglobinuria 
(PNH) 
Note 
Decrease or absence of glycosylphosphatidylinositol-
anchored molecules from the surface of the affected  
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cells, such as CD59 (and CD55), resulting in chronic 
intravascular hemolysis, cytopenia and increased 
tendency to thrombosis, venous thrombosis, deficient 
hematopoiesis and, rarely, leukemic conversion. 
Disease 
PNH involves the defective synthesis of a 
glycosylphosphatidylinositol (GPI) anchor that is ued 
by certain surface proteins for tethering to the cell
membrane, such as CD59 (Meri and Jarva, 1998). 
Somatic mutations in the X-linked gene PIGA (GPI 
complementation group A) which encodes a protein 
required in the biosynthesis of GPI molecules, have 





Possible association between paroxysmal nocturnal 
hemoglobinuria phenotype and lymphoproliferative 
syndromes (Meletis et al., 2001). 
Alzheimer's disease (AD) 
Note 
It was demonstrated at both protein and mRNA levels 
that CD59 expression in frontal cortex and 
hippocampus in AD brains was significantly decreased 
when compared with normal age matched non-
demented individuals, supporting the hypothesis that
AD brains are particularly vulnerable to complement-
mediated neuronal death (Yang et al., 2000). 
Disease 
AD is a neurodegenerative disease that causes changes 
in brain function.  
AD usually affects people over the age of 65 years, 
with a progressive decline in memory, thinking, 
language and learning capacity. Age is the strongest 
predictor for the development and progression of AD 
(Tanna, 2004). 
Prognosis 
AD is incurable. It leads to death within an averag of 
eight years after diagnosis, the last three of which are 
typically spent in an institution. 
Cytogenetics 
The molecular mechanisms and hypotheses of AD can 
be incredibly complex.  
One of the key events leading to AD appears to be the 
formation of a peptide (protein) known as amyloid beta 
(beta amyloid, Aβ), which clusters into amyloid 
plaques (senile plaques) on the blood vessels and on the 
outside surface of neurons of the brain.  
This plaques have been shown to activate the 
complement system (Kolev et al., 2009). 
Breast cancer 
Disease 
Human breast cancer cells are protected from 
complement-dependent lysis (CDC) by overexpression 
of CD59 (Yu et al., 1999). It has been shown in 
numerous studies that inhibition/neutralization of CD59 
on breast tumour cells increases tumour killing by 
complement system both in vivo and in vitro. 
Prognosis 
A recent comparative proteomics study provided novel 
insights into key proteins associated with the metasta ic 
potential of breast cancer cells and identified CD59 as a 
marker for breast cancer aggressiveness (Terp et al., 
2012). 
Oncogenesis 
Overexpression of CD59 on the surface of tumour cells 
confers resistance to CDC which has been suggested to 




CD59 is strongly expressed in the ovarian tumor tissue  
and their associated cell lines cells in all 28 benign and 
malignant tumors examined (Bjørge et al., 1997).  
Neutralization of CD59 with an anti-CD59 monoclonal 
antibody or inhibition of cd59 expression by siRNA 
significantly enhances CDC of the ovarian cell lines 
(Kolev et al., 2011). 
Prognosis 
Significant reduced levels of CD59 were detected in the 
urine of patients with ovarian carcinoma compared to 
the control subjects (Abdullah-Soheimi et al., 2010).  
Thus, CD59 can be used as a biomarker in the 
development of noninvasive assays for diagnosis and 
screening for ovarian carcinoma. 
Oncogenesis 
It has been demonstrated that overexpression of CD59 
on cancer cell surface promotes tumour growth in vitro 
and in vivo by protecting them from complement lysis 
(Chen et al., 2000; Donev et al., 2006). 
Various cancers 
Note 
Complement is one of the main mediators of antibody-
based cancer therapy via the CDC effect. Tumour cells
overexpress CD59 which plays a critical role in 
resistance to CDC and monoclonal antibody-therapy 
for treatment of cancer (Juhl et al., 1997; Yan et al., 
2008). 
Disease 
CD59 is overexpress on the surface of different tumo r 
types and their associated cell lines –  
colorectal cancer (Thorsteinsson et al., 1998), B-cell 
leukemias (Treon et al., 2001), neuroblastoma (Donev 
et al., 2008), prostate cancer (Jarvis et al., 1997), 
malignant melanoma (Weichenthal et al., 1999), lung 
carcinoma (Varsano et al., 1998), etc. 
Prognosis 
In general, overexpression of CD59 on tumour surface 
is associated with poor prognosis. 
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Oncogenesis 
It has been demonstrated that overexpression of CD59 
on cell surface promotes tumour growth in vitro and i  
vivo by protecting them from complement lysis (Chen 
et al., 2000; Donev et al., 2006). 
Diabetes 
Note 
Glycation was shown to inhibit CD59 function. In 
presence of glycation on CD59 it loses its MAC-
inhibitory function and results in vascular 
proliferavative complications like diabetes (Davies t 
al., 2005). Loss of functional CD59 in hyperglycaemics 
contributes to their susceptibility to lysis by 
complement. Thus, it was suggested that glycation-
induced inactivation of CD59 is a factor contributing to 
anaemia in type I diabetes. It is hypothesized that 
glycation near residue K41 and W40, two highly 
conserved amino acids essential for the CD59 functio , 
inhibits CD59 function (Davies et al., 2005). 
Disease 
Diabetes is a disease due to an increased level in 
glucose, which results in glycation and impairment of 
protein function. Glycation is when a sugar molecul 
binds a protein or a lipid molecule without the contr l 
of an enzyme. 
Age-related macular degeneration 
(AMD) 
Note 
Immunohistochemical studies have localized activated 
complement components, including the membrane 
attack complex (MAC) in retinal pigment epithelium 
(RPE) and drusen in the eyes of patients with AMD 
(Johnson et al., 2000). CD59 protects autologous cell 
killing by preventing the formation of lytic MAC on 
the cell membrane (Meri et al., 1990).  
The expression of CD59 was found to be significantly 
lower on CD14(+) monocytes in patients with 
neovascular AMD compared with controls (Singh et 
al., 2012). Introduction of human CD59 using 
adenoviral vectors as a possible therapeutic strategy has 
been proposed (Ramo et al., 2008). 
Disease 
Molecular basis for AMD is not well understood, a 
growing body of evidence has recently implicated 
inflammatory processes, specifically the complement 
system, in the pathogenesis of this disease (Johnson et 
al., 2000). 
Prognosis 
AMD is the leading cause of blindness among the 
elderly in industrialized nations (Klein et al., 2008). 
Major depression 
Note 
Expression of CD59 has been found significantly 
inhibited in an animal model of major depression (Pajer 
et al., 2012). This suggests that neurons become mor
susceptible to complement-mediated damage. 
Disease 
Early-onset major depressive disorder (MDD) is a 
serious psychiatric condition occurring in people under 
25 years of age. Early onset of MDD predicts greater 
familial risk, suggesting a substantial genetic etiology. 
Approximately 1% of the population of 12 years has 
MDD, but rates increase to 17-25% by late adolescence 
and young adulthood (Pajer et al., 2012). 
Breakpoints 
Note 
Chromosomal in situ hybridization and pulsed field gel
electrophoresis mapped the CD59 gene to 11p13, distal 
to the breakpoint of acute TCL2 (T-Cell Leukemia) and 
proximal to the Wilms tumor gene (WT1) (Heckl-
Ostreicher et al., 1993). 
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